CHARISMA May Make Bayer Primary MI Prevention Petition More Popular
This article was originally published in The Tan Sheet
Executive Summary
Bayer's bid for an indication for the primary prevention of MI on professional aspirin labeling may be strengthened by data from the CHARISMA trial
You may also be interested in...
Aspirin Use For CVD Prevention Low Among At-Risk Patients – Study
A survey on aspirin use for cardiovascular disease prevention shows low usage "even among patients at increased risk" and could encourage FDA to act on a Bayer's 2003 citizen petition to include a primary prevention indication in professional labeling for aspirin, a researcher says
Aspirin Use For CVD Prevention Low Among At-Risk Patients – Study
A survey on aspirin use for cardiovascular disease prevention shows low usage "even among patients at increased risk" and could encourage FDA to act on a Bayer's 2003 citizen petition to include a primary prevention indication in professional labeling for aspirin, a researcher says
Aspirin Use For CVD Prevention Low Among At-Risk Patients – Study
A survey on aspirin use for cardiovascular disease prevention shows low usage "even among patients at increased risk" and could encourage FDA to act on a Bayer's 2003 citizen petition to include a primary prevention indication in professional labeling for aspirin, a researcher says